p53 status and response to chemotherapy;Statut tumoral de p53 et réponse à la chimiothérapie

Bulletin du Cancer

Volumn 89, Issue 12, 2002, Pages 1007-1010

  Bénard, Jean ^b   Ahomadégbé, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

Breast cancer; Chemotherapy; p53 status; Therapeutic response

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PROTEIN P53;

APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER TISSUE; CLINICAL TRIAL; CYTOSTASIS; CYTOTOXICITY; DRUG EFFICACY; GENE MUTATION; HUMAN; PROTEIN CONTENT; PROTEIN FUNCTION; REVIEW; SENESCENCE; TISSUE TYPES; TREATMENT OUTCOME; WILD TYPE;

ANTINEOPLASTIC AGENTS; GENES, P53; HUMANS; NEOPLASMS;

EID: 0036965297     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Ellis P, Smith L, Ashley S, Walsh G, Ebbs S, Baum M, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998; 16: 107-14.
2. Robert J. New concepts for the study of anticancer drug resistance. Bull Cancer 2002; 89: 17-22.
3. Larsen CJ. Actualités sur les mécanismes moléculaires de la carcinogenèse. Bull Cancer 1998; 85: 9-19.
4. Soussi T. Fiches signalétiques des oncogènes et des gènes suppresseurs. Bull Cancer 1998 à 2001.
5. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
6. Lane D. How cells choose to die. Nature 2001; 414: 25-7.
7. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nature Rev Cancer 2002; 2: 594-604.
8. Soussi T, Béroud D. Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Rev 2001; 1: 18.
9. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
10. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
11. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263-9.
12. Jacquemier J, Penault-Llorca F, Viens P, Houvenaeghel G, Hassoun J, Torrente M, et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 1994; 14: 277-8.
13. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, Demascarel L, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 1996; 74: 1458-65.
14. Thorlacius S, Thorgilsson B, Bjornsson J, Ttyggvadottir L, Borresen AL, Ogmundstottir HM, et al. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 1995; 31: 1856-61.
15. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50-6.
16. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci 1997; 94: 9679-83.
17. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW, et al. Loss of normal p53 function confers sensitisation to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72-9.
18. Hawkins DS, Demers GW and Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56: 892-8.
19. Wu GS, El-Deiry WS. P53 and chemosensitivity. Nature Med 1996; 2: 255-6.
20. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811-4.
21. Geisler S, Lenning PE, Aas T, Johnsen H, Fluge O, Faksvag Haugen D, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-12.
22. Bertheau P, Plassa F, Espié M, Turpin E, de Roquancourt A, Marty M, et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360: 852-4.
23. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, et al. A simple p53 functional assay fro screening cell lines, blood and tumors. Proc Natl Acad Sci 1995; 92: 3963-7.
24. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-46.
25. Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419: 729-34.